Abstract
In recent years, our understanding of the molecular interaction of collagens with their cognate integrin receptors has remarkably improved. Structural elucidations of both the integrin and the collagenous triple helix have contributed to this achievement. The structures of an entire integrin ectodomain and of an A-domain, which is unique to the integrin α subunits of collagen-binding and leukocyte integrins, have been resolved crystallographically. Furthermore, a complex of such an integrin α subunit A-domain with its collagenous binding partner has revealed their interaction on the molecular level and gave first evidence in the conformational alterations which may convey the signal of ligand occupancy through the integrin into the cells. In parallel, the tissue distribution and biological functions of collagen-binding integrins have been characterised. Nowadays, the contribution of distinct integrins to different physiological and pathological processes is known. Among the best studied examples is the collagen-induced platelet activation and aggregation, in which α2β1 integrin is involved. Together with α1β1 integrin, it also plays a role in inflammatory processes. To manipulate processes which are mediated by collagen-binding integrins, compounds are developed which mimic the collagen ligand. Not only the structural information of the integrin:collagen-interaction but also improvements in the chemical synthesis of a collagenous triple helix facilitate the development of agonists and antagonists of collagen-binding integrins. Furthermore, another impact in this search comes from the discovery of high-affinity inhibitors from venoms, which lack a collagenous triple-helix.
Keywords: integrin, collagen, disintegrin, integrin agonist, integrin antagonist, cell-matrix interaction
Current Pharmaceutical Design
Title: Collagen-Binding Integrins as Pharmaceutical Targets
Volume: 11 Issue: 7
Author(s): Johannes A. Eble
Affiliation:
Keywords: integrin, collagen, disintegrin, integrin agonist, integrin antagonist, cell-matrix interaction
Abstract: In recent years, our understanding of the molecular interaction of collagens with their cognate integrin receptors has remarkably improved. Structural elucidations of both the integrin and the collagenous triple helix have contributed to this achievement. The structures of an entire integrin ectodomain and of an A-domain, which is unique to the integrin α subunits of collagen-binding and leukocyte integrins, have been resolved crystallographically. Furthermore, a complex of such an integrin α subunit A-domain with its collagenous binding partner has revealed their interaction on the molecular level and gave first evidence in the conformational alterations which may convey the signal of ligand occupancy through the integrin into the cells. In parallel, the tissue distribution and biological functions of collagen-binding integrins have been characterised. Nowadays, the contribution of distinct integrins to different physiological and pathological processes is known. Among the best studied examples is the collagen-induced platelet activation and aggregation, in which α2β1 integrin is involved. Together with α1β1 integrin, it also plays a role in inflammatory processes. To manipulate processes which are mediated by collagen-binding integrins, compounds are developed which mimic the collagen ligand. Not only the structural information of the integrin:collagen-interaction but also improvements in the chemical synthesis of a collagenous triple helix facilitate the development of agonists and antagonists of collagen-binding integrins. Furthermore, another impact in this search comes from the discovery of high-affinity inhibitors from venoms, which lack a collagenous triple-helix.
Export Options
About this article
Cite this article as:
Eble A. Johannes, Collagen-Binding Integrins as Pharmaceutical Targets, Current Pharmaceutical Design 2005; 11 (7) . https://dx.doi.org/10.2174/1381612053381738
| DOI https://dx.doi.org/10.2174/1381612053381738 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Accelerating Cancer Drug Discovery Using Artificial Intelligence and In Silico Methods
Artificial intelligence and in silico methods speed up cancer drug discovery, transforming how new treatments are developed. Artificial intelligence, along with in silico methods, allows for quick investigation of large biological datasets, helping identify potential drug targets with remarkable speed and accuracy. Machine learning models help us understand how molecules ...read more
Artificial Intelligence and Computational Approaches in Drug Discovery
Computer-aided drug design (CADD) and artificial intelligence (AI) are fundamentally reshaping drug discovery pipelines by significantly enhancing efficiency in molecular screening, rational drug design, and natural product development. In the field of molecular screening, the integration of virtual high-throughput screening with advanced AI models enables rapid analysis of million-compound libraries, ...read more
Artificial Intelligence for Transformative Healthcare: From Prediction to Prevention
Machine learning and deep learning are transforming biomedical diagnosis by allowing for quicker and more accurate disease detection, ultimately enhancing patient care. Using advanced algorithms and extensive medical data, these approaches uncover patterns that may not be visible to humans, resulting in better detection of conditions such as cancer and ...read more
Mapping Dynamic Sites and Designing Novel Therapeutics
The concept of allostery, where ligand binding at a site distinct from the active or orthosteric site modulates protein function, has emerged as a transformative paradigm in modern drug discovery. Unlike conventional orthosteric drugs that often face limitations in selectivity and off-target effects, allosteric modulators offer a promising alternative. Their ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current and Future Medical Therapy, and the Molecular Features of Adrenocortical Cancer
Recent Patents on Anti-Cancer Drug Discovery Anti-Tumor Activity and Underlying Mechanism of Phomoxanthone B in MCF7 Cells
Anti-Cancer Agents in Medicinal Chemistry Immunoglobulin G Expression and its Potential Role in Primary and Metastatic Breast Cancers
Current Molecular Medicine New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Lipophilic Statins as Anticancer Agents: Molecular Targeted Actions and Proposal in Advanced Gynaecological Malignancies
Current Drug Targets Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Neonatal Germ Cell Tumors
Current Pediatric Reviews BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design Gene Directed Enzyme Prodrug Therapy for Ovarian Cancer: Could GDEPT Become a Promising Treatment Against Ovarian Cancer?
Anti-Cancer Agents in Medicinal Chemistry Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens
Combinatorial Chemistry & High Throughput Screening The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Role of Forkhead Transcription Factors of the O Class (FoxO) in Development and Progression of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets





